NA
CMD

Navellier & Associates’s Cantel Medical Corporation CMD Stock Holding History

Navellier & Associates’s Portfolio CMD Stock Details CMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,724
Closed -$251K – 317
2018
Q3 		$251K Sell
2,724
-92
-3% -$8.76K 0.03% 250
2018
Q2 		$277K Sell
2,816
-42
-1% -$4.7K 0.04% 251
2018
Q1 		$318K Sell
2,858
-75
-3% -$8.41K 0.05% 222
2017
Q4 		$302K Sell
2,933
-56
-2% -$5.58K 0.06% 224
2017
Q3 		$281K Sell
2,989
-538
-15% -$42.5K 0.05% 192
2017
Q2 		$275K Sell
3,527
-596
-14% -$44.8K 0.04% 249
2017
Q1 		$330K Sell
4,123
-57,173
-93% -$4.54M 0.05% 235
2016
Q4 		$4.83M Buy
61,296
+346
+0.6% +$26.9K 0.8% 38
2016
Q3 		$4.75M Buy
60,950
+8,791
+17% +$638K 0.68% 52
2016
Q2 		$3.58M Buy
52,159
+16,481
+46% +$1.14M 0.54% 56
2016
Q1 		$2.55M Buy
+35,678
New +$2.24M 0.33% 58

Other funds holding CMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Navellier & Associates's CMD Position: Q4 2018 in Review

Navellier & Associates sold out of Cantel Medical Corporation (CMD) in Q4 2018, closing a stake of 2,724 shares — an estimated $251K sold.

Navellier & Associates first reported a position in CMD in Q1 2016 and held it in 11 quarters. The position peaked at $4.83M in Q4 2016. 253 funds tracked by Wall St. Rank hold CMD as of Q4 2018.

  • Navellier & Associates reported no remaining Cantel Medical Corporation position as of Q4 2018 after selling out during the quarter.
  • Navellier & Associates sold 2,724 Cantel Medical Corporation shares in Q4 2018, an estimated $251K.
  • Navellier & Associates first reported a position in Cantel Medical Corporation in Q1 2016 and held it in 11 quarters.
  • Navellier & Associates's Cantel Medical Corporation position peaked at $4.83M in Q4 2016.
  • 253 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q4 2018.

Based on Navellier & Associates's 13F filing for Q4 2018, filed 15 Jan 2019.